  The pharmaceutical Research and development (R&D) process is lengthy and
costly, taking nearly a decade to bring a new drug to the market. However,
advancements in biotechnology, computational methods, and machine learning
algorithms have the potential to revolutionize drug discovery, speeding up the
process and improving patient outcomes. The COVID-19 pandemic has further
accelerated and deepened the recognition of the potential of these techniques,
especially in the areas of drug repurposing and efficacy predictions.
Meanwhile, non-small molecule therapeutic modalities such as cell therapies,
monoclonal antibodies, and RNA interference (RNAi) technology have gained
importance due to their ability to target specific disease pathways and/or
patient populations. In the field of RNAi, many experiments have been carried
out to design and select highly efficient siRNAs. However, the established
patterns for efficient siRNAs are sometimes contradictory and unable to
consistently determine the most potent siRNA molecules against a target mRNA.
Thus, this paper focuses on developing machine learning models based on the
cheminformatics representation of the nucleotide composition (i.e. AUTGC) of
siRNA to predict their potency and aid the selection of the most efficient
siRNAs for further development. The PLS (Partial Least Square) and SVR (Support
Vector Regression) machine learning models built in this work outperformed
previously published models. These models can help in predicting siRNA potency
and aid in selecting the best siRNA molecules for experimental validation and
further clinical development. The study has demonstrated the potential of
AI/machine learning models to help expedite siRNA-based drug discovery
including the discovery of potent siRNAs against SARS-CoV-2.
